STL Volume 31 Number 3

Exosomes are emerging as a promising biologic platform in dermatology, with growing evidence supporting their role in wound healing, skin regeneration, pigmentation control, and inflammatory skin disorders through immune modulation and tissue repair mechanisms.

Discover how zasocitinib, a next-generation selective TYK2 inhibitor, may redefine psoriasis treatment with targeted efficacy, reduced off-target JAK effects, and promising late-stage clinical results.

Update on Icotrokinra 200 mg tablet (Icotyde™), Difamilast 1% ointment (Adquey™), and Epinephrine nasal spray 2 mg/0.1 mL (Neffy®).

Erratum to the deuruxolitinib for alopecia areata review, including revised safety data, launch information, and clinical comparisons.